Development of GPCR nanobodies

Among the numerous genes in the genome, 20% to 30% of the genes encode membrane proteins. Many membrane proteins are involved in almost every life activity in cells, including ligand-receptor binding, signal transduction, molecular transport, intercellular recognition and enzyme catalysis, and have wide application value in biological research and drug development. Therefore, membrane proteins are important targets for many drug development and clinical treatment research. Ion channels, transporters, GPCRs and kinases are the largest class of drug targets in drug development. According to statistics, about 50% of drugs target molecules are membrane proteins. However, due to the existence of problems such as low expression, insolubility in vitro, unstable purification, and difficulty in maintaining natural conformation, the application of transmembrane proteins in drug development is limited.

AlpVHHs has built a membrane protein antibody R&D platform, which can provide immunization methods based on overexpression cell lines, plasmids, VLPs, micelle, Nanodisc, SMALPS, Salipro, adenovirus, mRNA, etc., and combined with AlpVHHs's unique water-soluble adjuvant (Adjuvant Camelid, Code: 600-000-001), it can effectively improve the success rate of immunization.

Service Process

Service Advantages

Membrane Protein Antibody Development Case